Virpax Pharmaceuticals, Inc. VRPX
Set alert
0.00 USD 0.00 0.00%
At close · Oct 29
0.45 +0.45 +56,125.00%
After hours · Oct 29, 4:00 PM ET
0.021 Day range 0.021
0.0001 52-week range 0.10
- YTD
- -92.79%
- 1 year
- -96.52%
- Open
- 0.021
- Prev close
- 0.0008
- Mkt cap
- 994
- Vol
- 51
- Avg vol
- 311
- EPS
- -5.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.021
- High
- 0.021
- Forward P/E
- -0.38
- Beta
- 1.09
- Short ratio
- 1.04
- Inst. own
- 1.90%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.54406
- 200-d avg
- 1.40
- 1y target
- 3.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -0.43; estimate 0; surprise —%
- Mar 21, 2025Split: 1 for 25
Signals (62)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| RSI: Overbought | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| RSI: Oversold | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| RSI: Overbought | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 8, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 21, 2026 | 6 months ago |
| SMA: Bearish | Apr 9, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| SMA: Bearish | Mar 25, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 25, 2026 | 7 months ago |
| SMA: Bullish | Mar 24, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 24, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| RSI: Oversold | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 24, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 23, 2025 | 10 months ago |
| RSI: Overbought | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 26, 2025 | 11 months ago |
| SMA: Bullish | Oct 21, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| SMA: Bearish | Oct 2, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| RSI: Oversold | Sep 11, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| RSI: Oversold | Jul 30, 2025 | 1 year ago |
| SMA: Bearish | Jul 22, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 22, 2025 | 1 year ago |
| RSI: Oversold | Jul 22, 2025 | 1 year ago |
| SMA: Bullish | Jun 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Mar 14, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 21, 2025 | 1 year ago |
| RSI: Oversold | Nov 25, 2024 | 1 year ago |
Key statistics
- Market cap
- 2.78M
- Enterprise value
- 1.13M
- Trailing P/E
- 0.00
- Forward P/E
- -0.38
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.21
- EPS (TTM)
- -7.24
- Beta
- 1.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.98M
- Total cash
- 1.87M
- Total debt
- 0
- Return on equity
- -362.29%
- Shares outstanding
- 8.09M
- Short % of float
- 7.65%
- 50-day average
- 0.54406
- 200-day average
- 1.40
Analyst view
Consensus: none
Price target (mean) 3.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
VRPX Revenue — quarterly 0
VRPX Net income — quarterly -3.39M
VRPX EPS — quarterly 12.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.43 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -1.75 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -2.75 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -5.10 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -2.70 | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | -1.30 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2024 | Maxim Group | down | Buy | Hold |
| Jul 19, 2024 | Maxim Group | up | Hold | Buy |
| May 22, 2024 | Maxim Group | down | Buy | Hold |
About Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- virpaxpharma.com
News
- Reviewing Virpax Pharmaceuticals (NASDAQ:VRPX) and Zomedica (OTCMKTS:ZOMDF)
- Financial Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) versus Merck KGaA (OTCMKTS:MKGAF)
- Nabriva Therapeutics (NASDAQ:NBRV) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Virpax Pharmaceuticals Announces Reverse Stock Split
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on VRPX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.39% | 31,382 | 10.79K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.35% | 27,971 | 9.62K | Sep 29, 2024 |
| UBS Group AG | 0.25% | 20,435 | 7.03K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.15% | 12,522 | 4.31K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 3,837 | 1.32K | Sep 29, 2024 |
| Signature Resources Capital Management, LLC | 0.00% | 50 | 17 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.31% | 25,474 | 8.76K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 8,756 | 3.01K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 6,629 | 2.28K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 6,857 | 2.36K | Oct 30, 2024 |